MARKETED
| Product: | MEMANTINE (Namenda®) |
| Indication: | Moderate-to-Severe Dementia and Alzheimer's Disease |
| Status: | May 2002 - Memantine approved for the treatment of
Alzheimer's Disease by the regulatory authorities in the
European Union. Sold by Merz Pharmaceuticals GmbH under the brand name Axura®. October 2003 - Memantine approved by U.S. FDA for moderate-to-severe Alzheimer's disease. Sold by Forest Laboratories under the brand name Namenda. Under an exclusive marketing arrangement, NTI has the right to receive royalty payments from Merz and its marketing partners. |
| Benefit: | Improvement in functional independence and reduction in required level of care. |
PHASE III
| Product: | VIPRINEX™ |
| Indication: | Ischemic Stroke |
| Status: | Currently enrolling. Completed a positive Phase II program and a statistically significant Phase III trial in the U.S., and a failed Phase III trial in Europe (multiple-day dosing regimens). To undergo additional Phase III testing with single-administration dosing. Over 2000 patients studied to date. |
| Benefit: | Minimize neurological damage and functional outcome while
limiting adverse effects (intracranial hemorrhage). Significantly
optimized safety and efficacy is expected with single-
administration dosing. 6-hour treatment window. |
| Product: | XERECEPT® (corticorelin acetate injection) XERECEPT is a novel agent being investigated for the treatment of brain swelling associated with brain tumors. XERECEPT is currently being evaluated in two pivotal Phase III clinical studies. The studies are being conducted in the United States and Canada. |
| Indication: | Peritumoral Brain Edema |
| Status: | Currently enrolling. |
| Benefit: | Improvement in functional independence and reduction
in required level of care. In November 2005, the company sold its rights to XERECEPT to Celtic Pharma. The company is assisting Celtic Pharma with the administration of the ongoing clinical trials and the company has the potential to receive milestone, royalty and revenue sharing payments, if XERECEPT is successfully developed. |